DRUG
Cohort Study for Patients Using Fuzeon (Enfuvirtide)
Status
Unknown
Phase
Not applicable
Enrollment
200
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The Radata-Fuzeon cohort is an observational cohort study to gain a better understanding of Fuzeon (Enfuvirtide) in daily clinical practice. Patients planned to take this drug in a new antiretroviral combination therapy (ART) are eligible to participate in this observation. Physicians may register patients online via the internet. They are offered to get an expert advice suggesting therapeutics for a new ART. Observation interval is every three month. However physicians are allowed to initiate new diagnostics, expert advice and therapeutic changes independently from these intervals if necessary. Total observation time for each patients is planned for two years.
Interventions
Treatment arms and agents.
PROCEDURE
Laboratory diagnostic (CD4-cells)
PROCEDURE
Laboratory diagnostics (HIV-1 viral load)
DRUG
antiretroviral co-medication beside Fuzeon
Timeline
From registration to results.
First posted
Sep 22, 2005
Study start
May 2003
Primary completion
Not reported
Study completion
Dec 2006
Results posted
Not reported
Registry updated
Oct 25, 2005
Outcomes
What the study measures.
Primary outcomes
Not reported in the indexed record.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 0 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Diagnosis of HIV-Infection * Planned to switch to a Fuzeon-containing antiretroviral therapy Exclusion Criteria: * Inability to understand or sign inform consent
Study locations
1 registered sites.
Germany. Showing up to 24 locations stored in the fast local snapshot.
Ifi-Institute for Interdisciplinary Infectiology
Hamburg, Germany
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Enfuvirtide.
NCT IDStudyPhase / statusEnrollmentUpdated
Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)
French National Agency for Research on AIDS and Viral Hepatitis · HIV Infections · AIDS
Phase 3
Completed
195
2026-04
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
French National Agency for Research on AIDS and Viral Hepatitis · HIV Infections
Phase 3
Completed
170
2026-04
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
ANRS, Emerging Infectious Diseases · HIV Infection · Liver Failure
Phase 1 / Phase 2
Completed
14
2026-04
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
French National Agency for Research on AIDS and Viral Hepatitis · Leukoencephalopathy, Progressive Multifocal · HIV Infections
Phase 2
Completed
30
2026-04
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy
University Hospital, Tours · HIV
Phase 3
Completed
224
2025-12
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
Gilead Sciences · HIV-1-infection
Phase 2 / Phase 3
Active, not recruiting
689
2025-10
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · HIV
Early Phase 1
Completed
11
2021-11
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
National Institute of Allergy and Infectious Diseases (NIAID) · HIV Infections
Phase 3
Completed
517
2021-11
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.